Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000514606p
Ethics application status
Submitted, not yet approved
Date submitted
25/04/2023
Date registered
18/05/2023
Date last updated
18/05/2023
Date data sharing statement initially provided
18/05/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
Topical nifedipine for post haemorrhoidectomy pain relief
Query!
Scientific title
Topical nifedipine for post haemorrhoidectomy pain relief: a randomised, prospective, double-blind placebo trial protocol
Query!
Secondary ID [1]
309519
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Haemorrhoidectomy
329802
0
Query!
Pain
329803
0
Query!
Condition category
Condition code
Surgery
326702
326702
0
0
Query!
Other surgery
Query!
Anaesthesiology
326703
326703
0
0
Query!
Pain management
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
To assess the efficacy of topical (0.5%) nifedipine ointment for reducing post haemorrhoidectomy pain. Participants will be instructed to apply a pea-sized amount of their ointment, using a glove, 1-1.5cm into the anus circumferentially, as well as to the external anus. This will be done twice a day for four weeks. Follow up will consist of post operative questionnaire's to complete.
Query!
Intervention code [1]
325950
0
Treatment: Drugs
Query!
Comparator / control treatment
Comparative placebo ointment consisting of pluronic lecithin organogel (PLO).
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
334566
0
Post operative pain will be the primary outcome. This will be assessed using a validated 10-point standardised visual analogue scale (VAS). Scores will range from zero (no pain at all) to ten (worst pain imaginable).
Query!
Assessment method [1]
334566
0
Query!
Timepoint [1]
334566
0
Using the 10-point standardised VAS, pain will be measured at the following timepoints:
i. pre-operatively (baseline)
ii. recovery (within the first 30 minutes post-operatively)
iii. 4 hours (discharge) post-operatively
iv. 24 and 48hours post-operatively
v. 1 and 4 weeks post-operatively
Query!
Secondary outcome [1]
421238
0
Secondary outcomes will include the initial time of rescue oxycodone analgesia usage. This will be assessed by patient records and patient reporting.
Query!
Assessment method [1]
421238
0
Query!
Timepoint [1]
421238
0
This will be the first time-point, within 4 weeks post-operartively, when the patient uses rescue oxycodone.
Query!
Secondary outcome [2]
421842
0
Secondary outcomes will include the total rescue oxycodone usage. This will be assessed by patient records and patient reporting.
Query!
Assessment method [2]
421842
0
Query!
Timepoint [2]
421842
0
This will be the total amount of oxycodone consumed within 4 weeks post-operatively.
Query!
Secondary outcome [3]
421843
0
Secondary outcomes will include the time to first defecation. This will be assessed by patient records and patient reporting.
Query!
Assessment method [3]
421843
0
Query!
Timepoint [3]
421843
0
This will be the first time-point, within 4 weeks post-operatively, when the patient defecates.
Query!
Secondary outcome [4]
421844
0
Secondary outcomes will include any adverse events. This will be assessed by patient records and patient reporting survey.
Query!
Assessment method [4]
421844
0
Query!
Timepoint [4]
421844
0
This will be measure over the 4 weeks post-operatively. These will included any of the following:
o readmission
o reoperation
o urinary retention requiring catherisation
o perianal bleeding
o perianal swelling or oedema
o faecal incontinence
o tenesmus
o headache
o light-headedness or dizziness
o peripheral oedema
Query!
Eligibility
Key inclusion criteria
Patients over the age of 18 who are planned for 3-column haemorrhoidectomy, by a closed technique, will be recruited by surgeons during either their initial consultation for haemorrhoidectomy surgery or on the day of planned surgery.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients who will not be included in the trial will be those who:
i. are under the age of 18
ii. are pregnant or breast feeding
iii. have concurrent non-haemorrhoidal anorectal disease
iv. have a known allergy to nifedipine
v. have comorbidities or take medications that are a contra-indication to nifedipine usage
vi. have impaired renal function where parecoxib is contra-indicated
vii. have a chronic pain condition requiring ongoing regular analgesia
viii. cannot provide informed consent
ix. cannot have a general anaesthetic
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Concealment of treatment and placebo ointments in de-identified, opaque and numbered containers.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated block randomisation.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3 / Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Sample calculation:
Compared to similar studies, pre-trial calculations established a required sample size of 48 (24 patients per group), based on alpha = 0.05 and power = 0.9 based on primary outcome (pain). Estimating an attrition rate of 20-25%, a sample size of 60 (30 per group) was chosen. The sample size was calculated utilizing STATA 17 (StataCorp, College Station, Texas 77845 USA) considering a two-tailed test.
Statistical analysis:
The statistical analysis for this study will be conducted using STATA 17 (StataCorp, College Station, Texas 77845 USA). To ensure the validity of our findings, we will first check the normality of the numeric variables using the Kolmogorov-Smirnov test, as well as descriptive measures of distribution such as skewness and kurtosis.
For presentation purposes, we will report mean (SD) for numeric normal variables, median (min-max) for non-normal variables, and frequency (percent) for categorical variables. To compare baseline measures and demographic variables between the two groups, we will use independent t-tests and Fisher-Freeman-Halton Exact tests where appropriate.
To assess the effect of the intervention, we will use two analysis of covariance (ANCOVA) models: model 1 will control for baseline measures (baseline adjusted), and model 2 will control for baseline measures and possible confounders (fully adjusted).
The study will utilize a two-way analysis of variance with repeated measures (RMANOVA) to evaluate the effect of the intervention, time, and their interactions on primary and secondary outcomes. The assumption of sphericity will be assessed using the Mauchly test and, to correct for any deviation from the assumption, Greenhouse-Geiser-based correction will be employed. Significant RMANOVA results will be followed by Sidak post-hoc tests.
We will also use an intention-to-treat (ITT) approach for all analyses, and will consider p values less than 0.05 to be statistically significant.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/07/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/05/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2024
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
24598
0
Cabrini Hospital - Malvern - Malvern
Query!
Recruitment postcode(s) [1]
40196
0
3144 - Malvern
Query!
Funding & Sponsors
Funding source category [1]
313713
0
University
Query!
Name [1]
313713
0
Cabrini Monash University (Department of Surgery)
Query!
Address [1]
313713
0
Cabrini Monash University Department of Surgery
154 Wattletree Road
Malvern, 3144
Victoria, Australia
Query!
Country [1]
313713
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Dr Christopher Steen
Query!
Address
Cabrini Monash University Department of Surgery
154 Wattletree Road
Malvern, 3144
Victoria, Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315522
0
None
Query!
Name [1]
315522
0
N/a
Query!
Address [1]
315522
0
N/a
Query!
Country [1]
315522
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
312886
0
Cabrini Research Governance
Query!
Ethics committee address [1]
312886
0
Research Governance Officer
Cabrini Research
Level 2, 154 Wattletree Rd
MALVERN VIC 3144
Query!
Ethics committee country [1]
312886
0
Australia
Query!
Date submitted for ethics approval [1]
312886
0
25/04/2023
Query!
Approval date [1]
312886
0
Query!
Ethics approval number [1]
312886
0
Query!
Summary
Brief summary
Haemorrhoidectomy (surgical removal of haemorrhoid) is a common surgical procedure carried out by general and colorectal surgeons worldwide. Pain following haemorrhoidectomy is universal and problematic, causing absenteeism from work and school as well as a hospital readmission for pain relief. This is thought to be related to spasm of the anal sphincter muscles or creation of an anal fissure. Topical medications to aid in pain relief are well studied and accepted due to their ready availability and low side effects. Calcium channel blockers (CCB), such as diltiazem and nifedipine, are available in topical preparation, and are thought to aid in pain relief by decreasing muscle spasm. Whilst there are some studies accessing the role of CCB in post haemorrhoidectomy pain relief, most are focussed on diltiazem. Interestingly, nifedipine has reported better healing rates in anal fissure than diltiazem. This study aims to ascertain the effectiveness of topical nifedipine versus placebo as a post operative adjunct in the hopes of reducing pain experienced and reducing the post-operative short-term disability associated with haemorrhoidectomy.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
126222
0
Dr Christopher Steen
Query!
Address
126222
0
Cabrini Monash University Department of Surgery
154 Wattletree Rd
Malvern, 3144
Victoria
Query!
Country
126222
0
Australia
Query!
Phone
126222
0
+61 395081786
Query!
Fax
126222
0
Query!
Email
126222
0
[email protected]
Query!
Contact person for public queries
Name
126223
0
Dr Christopher Steen
Query!
Address
126223
0
Cabrini Monash University Department of Surgery
154 Wattletree Rd
Malvern, 3144
Victoria
Query!
Country
126223
0
Australia
Query!
Phone
126223
0
+61 395081222
Query!
Fax
126223
0
Query!
Email
126223
0
[email protected]
Query!
Contact person for scientific queries
Name
126224
0
Dr Christopher Steen
Query!
Address
126224
0
Cabrini Monash University Department of Surgery
154 Wattletree Rd
Malvern, 3144
Victoria
Query!
Country
126224
0
Australia
Query!
Phone
126224
0
+61 395081222
Query!
Fax
126224
0
Query!
Email
126224
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
All de-identified individual line-by-line data.
Query!
When will data be available (start and end dates)?
Immediately following publication, no end date determined.
Query!
Available to whom?
Researchers who provide a sound proposal.
Query!
Available for what types of analyses?
Meta-analyses.
Query!
How or where can data be obtained?
By contact with principal investigation (
[email protected]
)
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF